Last reviewed · How we verify
Persistence of Influenza Vaccine-induced Antibody in Lung Transplant Patients and Healthy Individuals Beyond the Season
This a sub-study of a 5-year study designed to investigate how antibody and T cell responses following influenza vaccine compare among lung transplant patients, patients waiting for lung transplantation, and healthy individuals. This study is designed to investigate influenza vaccine-induced antibodies in lung transplant patients beyond the season of vaccination.
Details
| Lead sponsor | University of Wisconsin, Madison |
|---|---|
| Status | COMPLETED |
| Enrolment | 100 |
| Start date | 2004-12 |
| Completion | 2009-07 |
Conditions
- Influenza
Interventions
- Influenza vaccine
Primary outcomes
- Antibody response to influenza vaccine — season 1 (up to 1 year on study)
Influenza antibody concentrations against viruses no longer included in the vaccine were measured in serum by hemagglutination inhibition assay (HIA) annually following vaccination of lung transplant participants and healthy controls. - Antibody response to influenza vaccine — season 2 (up to 2 years on study)
Influenza antibody concentrations against viruses no longer included in the vaccine were measured in serum by hemagglutination inhibition assay (HIA) annually following vaccination of lung transplant participants and healthy controls. - Antibody response to influenza vaccine — season 2 (up to 2.5 years on study)
Influenza antibody concentrations against viruses no longer included in the vaccine were measured in serum by hemagglutination inhibition assay (HIA) annually following vaccination of lung transplant participants and healthy controls. - Antibody response to influenza vaccine — season 3 (up to 3 years on study)
Influenza antibody concentrations against viruses no longer included in the vaccine were measured in serum by hemagglutination inhibition assay (HIA) annually following vaccination of lung transplant participants and healthy controls.
Countries
United States